Skip to main content

BioTrove Inks Screening Deal with Blue Sky

NEW YORK, March 24 (GenomeWeb News) - BioTrove and Blue Sky will collaborate to create a screening portfolio for challenging drug targets, Biotrove said this week.


Under the agreement, BioTrove will use Blue Sky proteins as a component of an assay used by BioTrove's RapidFire platform to screen for biomarkers.


The collaboration will focus initially on targets in metabolic disorders and oncology, BioTrove said.


Financial details were not provided.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.